SOURCE: Cannabis Science Inc.

September 14, 2010 10:22 ET

Cannabis Science Hails Israel's Expansion of Medical Cannabis Program, Health Ministry Expects "Tens of Thousands to Be Treated" Inclusion of Veterans With PTSD Supports Cannabis Science Plans

COLORADO SPRINGS, CO--(Marketwire - September 14, 2010) -  Cannabis Science, Inc. (OTCBB: CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is hailing the news that the Israeli Health Ministry is greatly expanding its medical marijuana program. The Israeli newspaper Ha'aretz reports that the Israeli Health Ministry is authorizing doctors from five different hospitals to prescribe medical marijuana to patients suffering from cancer and chronic pain.

Cannabis Science President and CEO Dr. Robert Melamede, PhD., noted, "Israeli scientists, in particular Dr. Rapahel Mechoulam and co-workers, have pioneered some of the most important research on cannabis and its medical and health implications. Their actions are in line with the growing tide of nations embracing the new cannabis science. Most recently, Germany announced that it was legalizing medical marijuana. Compared to the US, the Israeli population is tiny, yet there are already thousands of national medical marijuana users, whereas the US has only the four remaining patients from a program that was terminated decades ago. It is shocking how slow the US government has been in creating federal policies based on cannabis science rather than on the paranoid fears of people who appear to be deficient in their endocannabinoid activity's regulation of their open-mindedness. How can the thousands of peer reviewed articles that describe the huge number of health conditions that could benefit from medical marijuana use continue to be ignored?"

The Ha'aretz newspaper added that in the future department managers in the Israeli health maintenance organizations would be able to prescribe medical marijuana to patients. The ministry estimated that this year there would be a two-thirds increase in the number patients, allowing treatment for about 5,000 patients. In the future the ministry expects tens of thousands of more to be treated with medical marijuana. Currently, 14 Israeli farms have been given permits to grow marijuana legally for medicinal use, but only three are currently operating.

Richard Cowan, Cannabis Science CFO, added, "Israel takes good care of its veterans and their actions should be further impetus for the Obama Administration to recognize that our troops also deserve the best medicine possible, and often that is cannabis. Most prescriptions for medical marijuana are given to patients suffering from chronic pain, including patients with fibromyalgia, cancer, HIV/AIDS, neurological disorders, multiple sclerosis, asthma and glaucoma, as well as to Israel Defense Forces veterans suffering from post-traumatic stress disorder."

Please visit:

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact Information